Sugi Predict

Sugi Predict / Compounds / SCHEMBL112113

SCHEMBL112113

SCHEMBL112113

CC(C)COc1cccc(N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.63
▸ TP53 P04637 1/20 0.63
▸ TSHR P16473 2/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ MAOB P27338 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ APP P05067 1/20 0.49
▸ MAPT P10636 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSP90AA1 P07900 1/20 0.46
▸ SIRT2 Q8IXJ6 1/20 0.46
▸ TRIM24 O15164 1/20 0.46
▸ NR1H4 Q96RI1 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ MAOA P21397 1/20 0.42
▸ PTGS1 P23219 1/20 0.42
▸ TLR8 Q9NR97 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Aminophenol SCHEMBL2372454 0.90 ALDH1A1 (0.53) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL2967940 0.86 TRIM24 (0.55) TSHRMAPTPOLBSIRT2TRIM24
SCHEMBL3544164 0.85 CYP3A4 (0.59) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL4958479 0.85 CYP3A4 (0.59) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL10635987 0.85 LMNA (0.61) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL28134466 0.84 CYP3A4 (0.46) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL25320768 0.82 CYP3A4 (0.56) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL25336536 0.82 CYP3A4 (0.56) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL30515013 0.82 CYP3A4 (0.56) CYP3A4TP53TSHRALDH1A1MAOB
SCHEMBL30515092 0.82 CYP3A4 (0.56) CYP3A4TP53TSHRALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559918-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2025-05-28 — — EP disclosed
EP-3673906-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2025-05-14 — — EP disclosed
WO-2021216998-A1 MODIFIED NUCLEOTIDES AND USES THEREOF Singular Genomics Systems, Inc. (US) 2021-10-28 — — WO disclosed
CN-107080747-B Glucosylceramide synthase inhibitors 建新公司 2021-02-26 — — CN disclosed
EP-3673906-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2020-07-01 — — EP disclosed
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2020-02-13 — — US disclosed
US-20160207933-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION 2016-07-21 — — US disclosed
US-9139580-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-22 — — US disclosed
US-9126993-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-08 — — US disclosed
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION 2014-12-18 — — US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 — — US disclosed
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-09-17 — — US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 — — EP disclosed
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-26 — — US disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 — — WO disclosed
US-4220357-A PRESSURE SENSITIVE OR HEAT SENSITIVE SYSTEMS STERLING DRUG INC. (US) 1980-09-02 — — US disclosed
US-4209618-A COLOR PRECURSORS IN PRESSURE-SENSITIVE DUPLICATING SYSTEMS AND HEAT-SENSITIVE MARKING SYSTEMS STERLING DRUG INC. (US) 1980-06-24 — — US disclosed
US-4096176-A Benzoylbenzoic acids STERLING DRUG INC. (US) 1978-06-20 — — US disclosed
US-4094877-A SUBSTITUTED 3,3-DIPHENYLPHTHALIDES AS COLOR PRECURSORS STERLING DRUG INC. (US) 1978-06-13 — — US disclosed
US-4032527-A COLOR PRECURSORS STERLING DRUG INC. (US) 1977-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048266-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CYP3A4 3780/4885TP53 1915/4885TSHR 2474/4885
US-20090233911-A2 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 CYP3A4 3900/4885TP53 4360/4885TSHR 3338/4885
US-20160207933-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CYP3A4 3855/4885TP53 1761/4885TSHR 2423/4885
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA CYP3A4 3855/4885TP53 1761/4885TSHR 2423/4885
US-20090054410-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PARK7 CYP3A4 3900/4885TP53 4360/4885TSHR 3338/4885
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP CYP3A4 3369/4885TP53 4071/4885TSHR 3125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback